CSF3 and neutropenia: However, in the observational study by Reinisch et al. [59], primary prophylaxis with G-CSF was allowed in high-risk patients, resulting in a significantly lower incidence of neutropenia compared to previous clinical trials where prevention of this AE was not allowed.